Related Experiment Videos
Tyrosine kinase chimeras for antigen-selective T-body therapy
1Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
Abstract:
Protein tyrosine kinases (PTKs) transmit activation signals in almost every cell type, including immune effector cells. The aberrant or constitutive activation of PTKs can often cause neoplastic transformation. The use of chimeric receptors based on PTKs may enable us to elucidate the signaling pathways of normal immune cells and other cell types, and the abnormal events that can lead to malignant transformation. In this review, we focus on antigen specific chimeric PTKs in which antibody-derived scFv are joined to the Syk family of PTKs. These chimeric receptors yielded reagents that can selectively redirect immune effector cells and specifically activate them to produce cytokines or lyse their target. The advantages of using such PTK-based chimeras to redirect lymphocytes to tumor targets and their potential as an immunotherapeutic approach to malignant disease is discussed.
Insights
Chimeric protein tyrosine kinases (PTKs) redirect immune cells to target cancer. These engineered receptors activate immune responses against tumors, offering potential cancer immunotherapy.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Protein tyrosine kinases (PTKs) are crucial for cell signaling, including in immune cells.
- Dysregulated PTK activity is linked to cancer development.
- Chimeric receptors offer a tool to study signaling pathways and abnormal cell growth.
Purpose of the Study:
- To review antigen-specific chimeric PTKs, focusing on antibody fragments linked to Syk family PTKs.
- To discuss the potential of PTK-based chimeras in cancer immunotherapy.
Main Methods:
- Review of literature on chimeric PTKs, specifically scFv-fused Syk family PTKs.
- Analysis of the function and application of these engineered receptors.
Main Results:
- Chimeric PTKs can redirect and activate immune effector cells, such as lymphocytes.
- These engineered receptors can induce cytokine production and target cell lysis.
- The reagents selectively target tumor cells.
Conclusions:
- PTK-based chimeras are effective reagents for redirecting lymphocytes to tumor targets.
- These chimeric receptors hold promise as an immunotherapeutic strategy for malignant diseases.